Fast And Scalable Fc Quantitation In Supernatants With The PAIA Fc Titer Assay

By Silvia Vidali, PhD, and Mark McPate, Molecular Devices

This content is brought to you by Molecular Devices, a Danaher Operating Company.

In the ever-evolving landscape of biopharmaceutical development, the demand for efficient, high-throughput tools for generating and analyzing culture samples continues to grow. The industry's shift towards automation and miniaturization is particularly evident in the screening of hundreds to thousands of clones during cell line development. Operating within the constraints of limited sample volumes in 96-well and 384-well plates, the need for rapid and insightful results is paramount.

Addressing this complexity, the Fc PAIA Titer assay emerges as a robust solution, offering a fast, cost-effective, and automatable technology that caters to the biopharmaceutical industry's quest for assays with streamlined workflows and minimal sample requirements. This plate-based assay, designed for monitoring titers of Fc-containing molecules such as monoclonal antibodies, aligns seamlessly with the goals of bioprocess development. Together, the PAIA assay and SpectraMax microplate readers represent a comprehensive solution for meeting the challenges of high-throughput Fc quantification, from cell line development to bioprocess optimization.

Discover how this synergy not only enhances efficiency but also supports the advancement of biopharmaceutical research and production.